In yesterday’s Wall Street session, Sage Therapeutics Inc. (NASDAQ:SAGE) shares traded at $36.21, down -13.47% from the previous session.
21 analysts cover Sage Therapeutics Inc. (NASDAQ:SAGE), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $105.00 and a low of $37.00, we find $61.00. Given the previous closing price of $41.84, this indicates a potential upside of 45.79 percent. SAGE stock price is now -28.26% away from the 50-day moving average and -17.46% away from the 200-day moving average. The market capitalization of the company currently stands at $2.20B.
The stock has received a hold rating from 9 analysts and a buy rating from 12. Brokers who have rated the stock have averaged $61.94 as their price target over the next twelve months.
With the price target enhanced from $40 to $60, RBC Capital Mkts Upgraded its rating from Sector Perform to Outperform for Sage Therapeutics Inc. (NASDAQ: SAGE).
In other news, Barrett Elizabeth, Director bought 1,000 shares of the company’s stock on May 09. The stock was bought for $50,500 at an average price of $50.50. Upon completion of the transaction, the Director now directly owns 1,000 shares in the company, valued at $36210.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 10, Director JONAS JEFFREY M sold 11,643 shares of the business’s stock. A total of $519,413 was realized by selling the stock at an average price of $44.61. This leaves the insider owning 121,981 shares of the company worth $4.42 million. Insiders disposed of 18,210 shares of company stock worth roughly $0.66 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SAGE stock. A new stake in Sage Therapeutics Inc. shares was purchased by LORD, ABBETT & CO. LLC during the first quarter worth $6,891,000. SPHERA FUNDS MANAGEMENT LTD. invested $5,612,000 in shares of SAGE during the first quarter. In the first quarter, CANDRIAM S.C.A. acquired a new stake in Sage Therapeutics Inc. valued at approximately $3,258,000. PLATINUM INVESTMENT MANAGEMENT LTD acquired a new stake in SAGE for approximately $2,749,000. CANADA PENSION PLAN INVESTMENT BOARD purchased a new stake in SAGE valued at around $2,292,000 in the second quarter. In total, there are 312 active investors with 88.70% ownership of the company’s stock.
On Wednesday morning Sage Therapeutics Inc. (NASDAQ: SAGE) stock kicked off with the opening price of $41.36. During the past 12 months, Sage Therapeutics Inc. has had a low of $32.13 and a high of $59.99. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 14.20, and a quick ratio of 14.20. The fifty day moving average price for SAGE is $50.16 and a two-hundred day moving average price translates $43.83 for the stock.
The latest earnings results from Sage Therapeutics Inc. (NASDAQ: SAGE) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$2.46, beating analysts’ expectations of -$2.5 by 0.04. This compares to -$2.07 EPS in the same period last year. The company reported revenue of $3.29 million for the quarter, compared to $1.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 108.22 percent. For the current quarter, analysts expect SAGE to generate $2.9M in revenue.
Sage Therapeutics Inc.(SAGE) Company Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
